We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
The use of AG129 mice for the evaluation of FDA-approved drugs with broad antiviral spectrum as a potential anti-flavivirus treatment.
- Authors
Farfan-Morales, Carlos Noe; Osuna Ramos, Juan Fidel; Reyes-Ruiz, José Manuel; Cordero-Rivera, Carlos Daniel; De Jesús-González, Luis Adrián; Palacios-Rápalo, Selvin Noé; Del Ángel, Rosa María
- Abstract
The Dengue (DENV) and Zika (ZIKV) viruses have been increasing in the last decade in the Americas. For lack of vaccines, FDA-approved drugs have been proposed in recent years to combat these viruses, most notably lipid-lowering drugs, which have demonstrated a wide in vitro antiviral spectrum. However, despite being safe, in vivo assays remain critical to reduce the risk of adverse effects during their use as antivirals. Therefore, the present study focuses on the advantages and disadvantages of using AG129 transgenic mice, triple knock-out for interferon alpha (INF-α), beta (INF-β) and gamma receptor (INFr-γ), as an in vivo model for the evaluation of candidate lipid-lowering drugs for treatment against flaviviruses. Immunodeficient AG129 mice showed the advantage of exhibiting clinical signs of ZIKV and DENV disease. However, we observed differences between females and males, during infection and lipid-lowering drug treatments, that should be considered. MET increased survival time and decreased disease severity of DENV-infected mice. Interestingly, MET did not counteract ZIKV disease in vivo; on the contrary, exacerbated severe signs were observed in females that require further study.
- Subjects
FLAVIVIRAL diseases; DENGUE; ZIKA virus infections
- Publication
Veterinaria México OA, 2024, Vol 11, p99
- ISSN
2448-6760
- Publication type
Abstract
- DOI
10.22201/fmvz.24486760e.2024.1305